Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease.

BACKGROUND Little is known about the effect of nonadherence among patients with coronary artery disease (CAD) on a broad spectrum of outcomes including cardiovascular mortality, cardiovascular hospitalizations, and revascularization procedures. METHODS This was a retrospective cohort study of 15,767 patients with CAD. Medication adherence was calculated as proportion of days covered for filled prescriptions of beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, and statin medications. Multivariable Cox regression assessed the association between medication nonadherence as a time-varying covariate and a broad range of outcomes, adjusting for demographics and clinical characteristics. Median follow-up was 4.1 years. RESULTS Rates of medication nonadherence were 28.8% for beta-blockers, 21.6% for ACE inhibitors, and 26.0% for statins. In unadjusted analysis, nonadherence to each class of medication was associated with higher all-cause and cardiovascular mortality. In multivariable analysis, nonadherence remained significantly associated with increased all-cause mortality risk for beta-blockers (hazard ratio [HR] 1.50, 95% CI 1.33-1.71), ACE inhibitors (HR 1.74, 95% CI 1.52-1.98), and statins (HR 1.85, 95% CI 1.63-2.09). In addition, nonadherence remained significantly associated with higher risk of cardiovascular mortality for beta-blockers (HR 1.53, 95% CI 1.16-2.01), ACE inhibitors (HR 1.66, 95% CI 1.26-2.20), and statins (HR 1.62, 95% CI 1.124-2.13). The findings of increased risk associated with nonadherence were consistent for cardiovascular hospitalization and revascularization procedures. CONCLUSIONS Nonadherence to cardioprotective medications is common in clinical practice and associated with a broad range of adverse outcomes. These findings suggest that medication nonadherence should be a target for quality improvement interventions to maximize the outcomes of patients with CAD.

[1]  J. Tu,et al.  Adherence With Statin Therapy in Elderly Patients With and Without Acute Coronary Syndromes , 2002 .

[2]  L. Køber,et al.  Nationwide trends in the prescription of beta-blockers and angiotensin-converting enzyme inhibitors after myocardial infarction in Denmark, 1995–2002 , 2005, Scandinavian cardiovascular journal : SCJ.

[3]  J. Steiner,et al.  A Systematic Review of the Literature , 2019, HIV/AIDS and Adolescents.

[4]  Harlan M Krumholz,et al.  ACC/AHA clinical performance measures for adults with ST-elevation and non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures on ST-Elevation and Non-ST-El , 2006, Journal of the American College of Cardiology.

[5]  R. Dobson,et al.  Adherence to statins, beta-blockers and angiotensin-converting enzyme inhibitors following a first cardiovascular event: a retrospective cohort study. , 2005, The Canadian journal of cardiology.

[6]  Jeannie K. Lee,et al.  Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. , 2006, JAMA.

[7]  J. Piette.  Interactive voice response systems in the diagnosis and management of chronic disease. , 2000, The American journal of managed care.

[8]  John E. Stollerman,et al.  A telecommunications system for monitoring and counseling patients with hypertension. Impact on medication adherence and blood pressure control. , 1996, American journal of hypertension.

[9]  David L McClure,et al.  Adherence to cardioprotective medications and mortality among patients with diabetes and ischemic heart disease , 2006, BMC cardiovascular disorders.

[10]  L. Osterberg,et al.  Adherence to medication. , 2005, The New England journal of medicine.

[11]  Sankey V. Williams,et al.  ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). , 2003, Circulation.

[12]  Use and adherence to beta‐blockers for secondary prevention of myocardial infarction: who is not getting the treatment? , 2004, Pharmacoepidemiology and drug safety.

[13]  Denys T. Lau,et al.  Oral antihyperglycemic medication nonadherence and subsequent hospitalization among individuals with type 2 diabetes. , 2004, Diabetes care.

[14]  J. Merenich,et al.  Lipid management in patients with coronary artery disease by a clinical pharmacy service in a group model health maintenance organization. , 2005, Archives of internal medicine.

[15]  H. Krumholz,et al.  ACC/AHA clinical performance measures for adults with ST-elevation and non-ST-elevation myocardial infarction. Commentary , 2006 .

[16]  R. Califf,et al.  Long-Term Adherence to Evidence-Based Secondary Prevention Therapies in Coronary Artery Disease , 2006, Circulation.

[17]  J. Piette,et al.  Impact of automated calls with nurse follow-up on diabetes treatment outcomes in a Department of Veterans Affairs Health Care System: a randomized controlled trial. , 2001, Diabetes care.

[18]  Peter J. Neumann,et al.  Long-term persistence in use of statin therapy in elderly patients. , 2002, JAMA.

[19]  P. Thompson,et al.  Magnetic resonance imaging of left atrial thrombus , 2002, Heart.

[20]  Richard H. Chapman,et al.  Predictors of adherence with antihypertensive and lipid-lowering therapy. , 2005 .

[21]  Ross T Tsuyuki,et al.  A meta-analysis of the association between adherence to drug therapy and mortality , 2006, BMJ : British Medical Journal.

[22]  J. Merenich,et al.  Clinical pharmacy cardiac risk service for managing patients with coronary artery disease in a health maintenance organization. , 2007, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[23]  H. Krumholz,et al.  National and State Trends in Quality of Care for Acute Myocardial Infarction Between 1994-1995 and 1998-1999 , 2003 .

[24]  D. Alter,et al.  Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. , 2007, JAMA.

[25]  L. Køber,et al.  Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. , 2006, European heart journal.